Business
HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents
HLS Therapeutics to Become Distributor of the Saladax MyCare™ Psychiatry Line inclu...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics to Become Distributor of the Saladax MyCare™ Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, June 1, 2020\n\n\n\nThe MyCare Insite is a point-of-care (POC) device that uses just a single drop of blood to measure the most commonly used antipsychotic drugs in patients' blood The MyCare Psychiatry Clozapine Assay Test Kit has been granted Market Authorization by the U.S FDA; no such product exists in the Canadian market today Tests for 5 additional POC antipsychotics are in the final stages of development Device is complementary to the Company's CNS/Psychiatry business TORONTO, June 1, 2020 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system (\"CNS\") and cardiovascular markets, announces that it has become the exclusive Canadian distributor for the MyCare™ Insite point-of-care device and its related line of diagnostic tests from Saladax Biomedical, Inc. (\"Saladax\") of Bethlehem, Pennsylvania.\nThe MyCare Insite is a point-of-care device that is intended to measure the blood levels of the most common antipsychotic drugs, clozapine, risperidone, quetiapine, aripiprazole, olanzapine and paliperidone. Similar to a blood glucose test, MyCare Insite is easy to use and requires only a single drop of blood taken by a finger stick to measure patient drug levels, providing results in just minutes. Tests to achieve such results today are often clinically impractical, complex, and costly in terms of time and money. MyCare Insite for clozapine has been launched in Europe and Saladax will file MyCare Insite for clozapine testing with Health Canada this year and expects to file tests for additional drug products thereafter.\n\"Measuring and monitoring clozapine levels and hematological parameters is considered an important step towards optimizing therapy for patients who are taking that medication1,\" said Dr. Gary Remington, MD, PhD, FRCPC...